$CNTB

HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, suggesting a 730.9% upside from the last close. The firm cited strong clinical data for rademikibart, showing an 81% reduction in treatment failure, and its unique approach to managing COPD exacerbations.

HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying 641% upside from the last close. The firm cited positive clinical data for rademikibart, showing significant improvements in asthma and COPD treatments, and external validation from NEJM publication of tozorakimab data. Recent analyst price targets for the company range from $5 to $7.

HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying a 614.5% upside from the last close. The firm cited strong clinical data and upcoming regulatory milestones as key catalysts. Recent analyst price targets range from $5 to $7.

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.

Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.

Connect Biopharma (CNTB) reported positive Phase 2 data for rademikibart, showing an 81% reduction in treatment failure and 85% fewer new COPD exacerbations vs. placebo. The drug also eliminated hospitalizations/ED visits. The company plans to discuss the results with the FDA and host a conference call today.

Connect Biopharma (CNTB) reported mixed Phase 2 asthma trial results. Rademikibart missed the primary endpoint (p=0.153) but showed lung-function improvement (p=0.023). The company plans to use this measure in Phase 3. CNTB has $31.5M in cash but faces development costs. FDA feedback and funding are key uncertainties.

Connect Biopharma's stock fell 33.6% to $1.145 after its Phase 2 asthma drug trial failed to meet the primary endpoint, despite showing some positive results. The company's drug, rademikibart, did not achieve statistical significance in reducing treatment failure rates. Analysts had previously set a $7.00 price target. The broader market also declined slightly.

Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT stud